미국의 수의 진단 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the united states veterinary diagnostics market size is projected to be USD 3.36 billion in 2025, USD 3.63 billion in 2026, and reach USD 5.52 billion by 2031, growing at a CAGR of 8.76% from 2026 to 2031.

This report is Segmented by Product (Consumables/Reagents, Instruments), Technology (Immunodiagnostics, Biochemistry, Molecular, Hematology, Urinalysis, Others), Animal Type (Companion Animals, Livestock), Application (Infectious Diseases, Endocrinology, Cardiology, Oncology, Others), and End User (Reference Labs, Hospitals/Clinics, POC/In-House, Research Institutes). Forecasts in Value (USD).

United States Veterinary Diagnostics Market Trends and Insights

Rising Companion Animal Health Spend

Pet insurance penetration in the United States reached 3.9% of the total pet population in 2024, covering 6.4 million dogs and cats, while gross written premiums exceeded USD 4.74 billion and rose 21.4% year over year. That still leaves most pets outside formal reimbursement, which means the United States veterinary diagnostics market continues to face a meaningful out-of-pocket limit on premium panel adoption. At the same time, insured households are more able to accept deeper diagnostic workups because accident and illness plans commonly cover testing costs tied to clinical evaluation. State-level standard setting through the Pet Insurance Model Act supports broader policy consistency and should make insurance easier to scale through the forecast period. The result is a market where premium visits are becoming more diagnostics-intensive, while uninsured visits remain more price sensitive across the United States veterinary diagnostics market.

Expansion of In-Clinic and Point-of-Care Testing

The United States veterinary diagnostics market is seeing faster growth in in-clinic testing because compact analyzers now fit both standard hospitals and smaller ambulatory models. Zomedica's TRUFORMA platform shows this shift clearly, as the system is built to deliver endocrine assays in a compact format that can work in practices with limited space and in mobile settings. As more practices place point-of-care systems, the revenue profile moves beyond one-time hardware sales and toward recurring consumable pull. This is important because point-of-care and in-house testing is the fastest-growing end-user channel, with forecast growth of 10.2% through 2031 in the United States veterinary diagnostics market. The broader effect is that faster in-house turnaround is becoming part of routine care expectations, especially where same-visit clinical decisions matter most.

Persistent Veterinarian and Laboratory Technician Shortages

The United States veterinary diagnostics market continues to face a supply constraint because companion-animal veterinarian numbers rose over the past decade, while mixed-animal and agricultural veterinarian numbers moved lower, widening the service gap in food-animal care. Federal capacity also weakened in 2025 when USDA APHIS lost more than 1,300 staff members, including a reported 20% to 30% of personnel at a key animal disease testing laboratory. That leaves commercial laboratories carrying more of the response burden during outbreaks, even though the United States veterinary diagnostics market still depends on veterinarians to collect, interpret, and follow up on samples. Technician shortages add another bottleneck because cytology, histopathology, and specialized lab workflows cannot yet be fully automated at a commercial scale. The pressure is strongest in rural livestock territories, where test demand exists but local clinical capacity remains too thin to convert all of that demand into steady revenue.

Other drivers and restraints analyzed in the detailed report include:

1. AI-Enabled Interpretation of Images and Bloodwork
2. Wider Use of Molecular and Rapid Assays in Routine Practice
3. High Cost of Advanced Diagnostics for Price-Sensitive Owners

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Consumables, kits, and reagents held 46.27% of the United States veterinary diagnostics market share in 2025, making them the largest product category by revenue. This position reflects the recurring nature of assay cartridges, slides, reagents, and test kits that follow every successful analyzer placement in the United States veterinary diagnostics industry. Once a clinic commits to a platform such as IDEXX Catalyst or Zoetis Vetscan, repeat ordering becomes a stable part of operating spend rather than a discretionary purchase cycle. The United States veterinary diagnostics market also benefits here from stronger diagnostic intensity per visit, because higher test depth lifts reagent use even when visit growth is modest.

Instruments are forecast to grow at 9.08% CAGR through 2031, which makes them the fastest-growing product segment in the United States veterinary diagnostics market. The current investment cycle is being supported by hardware replacement, AI-enabled imaging upgrades, and demand for compact systems that fit smaller footprints. IDEXX's January 2026 launch of the ImageVue DR50 Plus added an imaging option with AI support and up to 60% lower radiation exposure than competing veterinary systems, which shows how vendors are using differentiated hardware to justify new placements. Corporate groups can absorb this capital spending more easily because they buy across many sites, while independents face the same competitive pressure with less pricing leverage. Over time, each new placement expands the downstream consumables tail, which keeps product growth in the United States veterinary diagnostics industry tied to both equipment refresh and recurring test use.

Immunodiagnostics led with 35.79% of revenue in 2025, supported by high-frequency use in infectious disease panels, vector-borne disease testing, heartworm screening, and allergy diagnostics. These assays have long been part of standard wellness and disease management protocols, which gives them broad installed-base support in both clinics and reference laboratories. Clinical biochemistry and hematology remain central to routine internal medicine because they support liver, kidney, endocrine, and complete blood count evaluation across large patient volumes. That steady test mix keeps mature technologies relevant even as the United States veterinary diagnostics market adds newer methods at the margin.

Molecular diagnostics are projected to grow at 8.38% CAGR through 2031, which makes them the fastest-expanding technology segment. USDA's National Milk Testing Strategy created a lasting role for PCR infrastructure in dairy herd surveillance after the December 2024 Federal Order. In companion animals, peer-reviewed validation has strengthened the case for liquid biopsy and related molecular tools in earlier cancer detection, including 98.7% specificity in a 2024 canine screening study. These parallel use cases matter because they reduce dependence on a single disease area or animal population. The technology mix is therefore widening the practical scope of the United States veterinary diagnostics market rather than replacing legacy formats outright.

Complete Report Scope:

• By Product
  • Consumables, Kits and Reagents
  • Instruments
• By Technology
  • Immunodiagnostics
  • Clinical Biochemistry
  • Molecular Diagnostics
  • Hematology
  • Urinalysis
  • Other Technologies
• By Animal Type
  • Companion Animals
    • Dogs
    • Cats
    • Other Companion Animals
  • Livestock
    • Cattle
    • Swine
    • Poultry
    • Other Livestock Animals
• By Application
  • Infectious Diseases
  • Endocrinology
  • Cardiology
  • Oncology
  • Other Applications
• By End User
  • Veterinary Reference Laboratories
  • Veterinary Hospitals and Clinics
  • Point-of-Care and In-House Testing
  • Veterinary Research Institutes and Universities

List of Companies Covered in this Report:

1. Agfa-Gevaert
2. Antech Diagnostics
3. Bionote
4. Bio-Rad Laboratories
5. bioMerieux
6. Covetrus
7. FUJIFILM
8. Heska
9. Henry Schein
10. IDEXX
11. INDICAL BIOSCIENCE GmbH
12. Neogen
13. QIAGEN
14. Randox Laboratories
15. Scil Animal Care Company
16. Shenzhen Mindray Animal Medical Technology Co., Ltd.
17. Siemens Healthineers
18. Thermo Fisher Scientific
19. Virbac
20. Zoetis

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Companion Animal Health Spend
  • 4.2.2 Expansion of In-Clinic and Point-of-Care Testing
  • 4.2.3 AI-Enabled Interpretation of Images and Bloodwork
  • 4.2.4 Wider Use of Molecular and Rapid Assays in Routine Practice
  • 4.2.5 Corporate Chain Standardization and Bulk Reagent Buying
  • 4.2.6 Under-Served Mobile and Ambulatory Veterinary Models
• 4.3 Market Restraints
  • 4.3.1 Persistent Veterinarian and Laboratory Technician Shortages
  • 4.3.2 High Cost of Advanced Diagnostics for Price-Sensitive Owners
  • 4.3.3 Fragmented Workflow Integration Across Practice Software and Devices
  • 4.3.4 Limited Reimbursement Visibility for Premium Diagnostics
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts

• 5.1 By Product
  • 5.1.1 Consumables, Kits and Reagents
  • 5.1.2 Instruments
• 5.2 By Technology
  • 5.2.1 Immunodiagnostics
  • 5.2.2 Clinical Biochemistry
  • 5.2.3 Molecular Diagnostics
  • 5.2.4 Hematology
  • 5.2.5 Urinalysis
  • 5.2.6 Other Technologies
• 5.3 By Animal Type
  • 5.3.1 Companion Animals
    • 5.3.1.1 Dogs
    • 5.3.1.2 Cats
    • 5.3.1.3 Other Companion Animals
  • 5.3.2 Livestock
    • 5.3.2.1 Cattle
    • 5.3.2.2 Swine
    • 5.3.2.3 Poultry
    • 5.3.2.4 Other Livestock Animals
• 5.4 By Application
  • 5.4.1 Infectious Diseases
  • 5.4.2 Endocrinology
  • 5.4.3 Cardiology
  • 5.4.4 Oncology
  • 5.4.5 Other Applications
• 5.5 By End User
  • 5.5.1 Veterinary Reference Laboratories
  • 5.5.2 Veterinary Hospitals and Clinics
  • 5.5.3 Point-of-Care and In-House Testing
  • 5.5.4 Veterinary Research Institutes and Universities

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Agfa-Gevaert N.V.
  • 6.3.2 Antech Diagnostics, Inc.
  • 6.3.3 BioNote, Inc.
  • 6.3.4 Bio-Rad Laboratories, Inc.
  • 6.3.5 bioMerieux SA
  • 6.3.6 Covetrus, Inc.
  • 6.3.7 FUJIFILM Holdings Corporation
  • 6.3.8 Heska Corporation
  • 6.3.9 Henry Schein, Inc.
  • 6.3.10 IDEXX Laboratories, Inc.
  • 6.3.11 INDICAL BIOSCIENCE GmbH
  • 6.3.12 Neogen Corporation
  • 6.3.13 QIAGEN N.V.
  • 6.3.14 Randox Laboratories Ltd.
  • 6.3.15 Scil Animal Care Company GmbH
  • 6.3.16 Shenzhen Mindray Animal Medical Technology Co., Ltd.
  • 6.3.17 Siemens Healthineers AG
  • 6.3.18 Thermo Fisher Scientific Inc.
  • 6.3.19 Virbac
  • 6.3.20 Zoetis Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment